Tempest Therapeutics Appoints New Directors to Address Nasdaq Compliance, Replaces CFO
Summary
Tempest Therapeutics announced the resignation of its CFO and appointed an internal replacement, alongside two new directors. These board appointments are a direct response to recent Nasdaq deficiency notices, significantly advancing the company's efforts to regain compliance and avoid delisting.
Key Events
-
CFO Resignation and Replacement
Mr. Nicholas Maestas resigned as Chief Financial Officer, effective June 5, 2026. Mr. Justin Trojanowski, the current Corporate Controller, Treasurer, and Principal Accounting Officer, was appointed as the new Vice President, Finance, Principal Financial Officer, and Corporate Secretary.
-
Two New Directors Appointed
Dr. John David Yee and Mr. William Drake Richey were appointed as Class II directors, effective June 4, 2026, filling existing vacancies on the Board. They will serve on the Audit, Compensation, and Nominating and Corporate Governance Committees.
-
Progress Towards Nasdaq Compliance
These director appointments directly address the Nasdaq deficiency notices received on May 22, 2026, regarding board and committee vacancies. The company believes it is now closer to regaining compliance with Nasdaq listing rules and mitigating delisting risk.
-
Director Compensation Policy Amended
The non-employee director compensation policy was amended to provide reduced annual cash retainers, although the newly appointed directors will each receive an initial option award to purchase 25,000 shares of common stock.
Analysis
This 8-K is important because it details concrete actions taken by Tempest Therapeutics to address critical corporate governance and compliance issues, particularly the Nasdaq deficiency notices received on May 22, 2026. The appointment of two new directors with relevant experience directly fills board vacancies, which is a key step towards regaining compliance and reducing the immediate risk of delisting. While the CFO's resignation is a notable event, the immediate internal replacement mitigates its negative impact. The company is trading near its 52-week low, making these steps towards stability particularly crucial for investor confidence.
At the time of this filing, TPST was trading at $1.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.2M. The 52-week trading range was $1.23 to $12.23. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.